A R T I C L E S
Brohm et al.
induces growth arrest of different cancer cell lines and arrest in
the G1 phase of the cell cycle or apoptosis.13,14
Because of these biological properties and its unique structure,
dysidiolide has been of intense interest to biologists, pharma-
cologists, and organic chemists,15 resulting in the completion
of five successful total syntheses since its discovery.
Results and Discussion
Planning of the Solid-Phase Synthesis. Dysidiolide is a
sesquiterpene with a decalin-type framework that carries a
lipophilic side chain terminating in an olefin and a hydrophilic
side chain incorporating an alcohol and a γ-hydroxybutenolide.
For the planned solid-phase synthesis, we intended to attach
the olefinic side chain to a robust linker that would provide the
terminal alkene structure after cleavage from the solid support
in a mild and traceless manner. The new olefin metathesis
linker4,16 incorporated in 2 was thought to fulfill these require-
ments (Scheme 1). Transition-metal catalyzed olefin metathesis
should liberate the desired compound accompanied by formation
of a polymer bound cyclopentene (step I, Scheme 1). Attachment
to the polymer via an ether bond was thought to provide the
required stability during the planned multistep synthesis. The
γ-hydroxybutenolide moiety should be obtained by addition of
3-lithiofuran to an aldehyde group and subsequent oxidation of
the heterocycle with singlet oxygen (step II, Scheme 1). For
the generation of the bicyclic core structure, it was planned to
apply the Diels-Alder route (step III, Scheme 1) previously
investigated in our laboratories15f and successfully employed
in total syntheses of natural dysidiolide in solution.15b-e The
knowledge gleaned from these studies suggested that this
cycloaddition primarily leads to the 6-epimer of the dysidiolide
framework. However, we chose to accept this deviation from
the goal of synthesizing the parent natural product itself, since
in the concept delineated above this is not necessarily required
to identify new biologically active compounds. It was planned
to synthesize the diene for the Diels-Alder reaction in solution
starting from commercially available chiral ketoester 8 and
attach it to the linker resin 5 carrying an aldehyde group by a
Wittig reaction with ylide 6 (step IV) in a convergent strategy
(4 w 5 + 6).
Figure 1. Activation of Cdk2-cyclin E complex by Cdc25A as essential
step for G1-S transition.
Here we describe the solid-phase synthesis of a close analogue
of the protein phosphatase inhibitor dysidiolide and of a small
library of dysidiolide analogues that rapidly yielded compounds
with significantly improved biological activity.5
The sesquiterpenoid dysidiolide 1 is a naturally occurring
inhibitor of the dual-specificity Cdc25 protein phosphatase
family that plays a crucial role in the regulation of the cell cycle.6
The Cdc25 phosphatases activate cyclin-dependent kinases
(Cdks) and thereby initiate progression of cells through different
phases of the cell cycle. For instance, Cdc25A activates the triply
phosphorylated complex between Cdk2 and cyclin E by
dephosphorylation of Cdk2 at Thr 14 and Tyr 15 (Figure 1).
Subsequently, the cells can progress beyond the G1/S check-
point.7 Similarly, Cdc25B and Cdc25C are thought to be
regulators of the G2/M transition through dephosphorylation and
activation of the Cdk1-cyclin B complex.8,9
The crucial roles of the Cdc25 dual specificity phosphatases
in cell-cycle regulation led to the notion that these enzymes
might be promising targets for the development of new
anticancer drugs.10,11 This prospect spurred studies aiming at
the development of selective Cdc25 inhibitors.12
Aldehyde resin 5 should be accessible from diol 717 by
coupling to Merrifield resin via Williamson ether formation and
subsequent oxidation of the remaining primary alcohol to the
aldehyde (step V, Scheme 1). The diene unit in 6 was traced
back to ketone 8 via addition of a vinyl Grignard to 8 followed
by elimination of the resulting tertiary alcohol. Formation of
the ylide was envisaged to be feasible by means of a nucleophilic
Among these, dysidiolide was identified as particularly
promising, since it inhibits Cdc25A with an IC50 value of 9.4
µM, whereas the phosphatases calcineurin, CD45, and LAR are
not inhibited by the natural product.13 In addition, dysidiolide
(5) Part of this work was published in preliminary form: Brohm, D.; Metzger,
S.; Bhargava, A.; Mu¨ller, O.; Lieb, F.; Waldmann, H. Angew. Chem., Int.
Ed. 2002, 41, 307-311.
(14) Danishefsky, S.; Magnuson, S. R.; Rosen, N. Patent WO 99/40079, 1999.
(15) (a) Corey, E. J.; Roberts, B. E. J. Am. Chem. Soc. 1997, 119, 12425-
12431. (b) Boukouvalas, J.; Cheng, Y.-X.; Robichaud, J. J. Org. Chem.
1998, 63, 228-229. (c) Magnuson, S. R.; Sepp-Lorenzino, L.; Rosen, N.;
Danishefsky, S. J. J. Am. Chem. Soc. 1998, 120, 1615-1616. (d) Takahashi,
M.; Dodo, K.; Hashimoto, Y.; Shirai, R. Tetrahedron Lett. 2000, 41, 2111-
2114. (e) Jung, M. E.; Nishimura, N. Org. Lett. 2001, 3, 2113-2115. (f)
Brohm, D.; Waldmann, H. Tetrahedron Lett. 1998, 39, 3995-3998. (g)
Miyaoka, H.; Kajiwara, Y.; Yamada, Y. Tetrahedron Lett. 2000, 41, 911-
914. (h) Piers, E.; Caille´, S.; Chen, G. Org. Lett. 2000, 2, 2483-2486. (i)
Demeke, D.; Forsyth, C. J. Org. Lett. 2000, 2, 3177-3179. (j) Paczkowski,
R.; Maichle-Mo¨ssmer, C.; Maier, M. E. Org. Lett. 2000, 2, 3967-3969.
(k) Takahashi, M.; Dodo, K.; Sugimoto, Y.; Aoyagi, Y.; Yamada, Y.;
Hashimoto, Y.; Shirai, R. Bioorg. Med. Chem. Lett. 2000, 10, 2571-2574.
(16) For the use of traceless linkers based on olefin metathesis see: (a) Peters,
J.-U.; Blechert, S. Synlett 1997, 348-350. (b) Knerr, L.; Schmidt, R. R.;
Synlett 1999, 1802-1804.
(6) Draetta, G.; Eckstein, J. Biochim. Biophys. Acta 1997, 1332 (2), M53-
M63.
(7) Hoffmann, I.; Draetta, G.; Karsenti, E. EMBO J. 1994, 13, 4302-4310.
(8) Nilsson, I.; Hoffmann, I. Prog. Cell Cycle Res. 2000, 4, 107-114.
(9) Millar, J. B.; Blewitt, J.; Gerace, L.; Sadku, K.; Featherstone, C.; Russell,
P. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 10500-10504.
(10) Eckstein, J. W. Gene Ther. Mol. Biol. 1998, 1, 707-711.
(11) Zhang, Z.-Y. Curr. Opin. Chem. Biol. 2001, 5, 416-423.
(12) (a) Cebula, R. E.; Blanchard, J. L.; Boisclair, M. D.; Pal, K.; Bockovich,
N. Bioorg. Med. Chem. Lett. 1997, 7, 2015-2020. (b) Dodo, K.; Takahashi,
M.; Yamada, Y.; Sugimoto, Y.; Hashimoto, Y.; Shirai, R. Bioorg. Med.
Chem. Lett. 2000, 10, 615-617. (c) Peng, H.; Zalkow, L. H. J. Med. Chem.
1998, 41, 4677-4680. (d) Peng, H.; Xie, W.; Kim, D.-I.; Zalkow, L. H.;
Powis, G.; Otterness, D. M.; Abraham, R. T. Bioorg. Med. Chem. 2000, 8,
299-306. (e) Peng, H.; Otterness, D. M.; Abraham, R. T.; Zalkow, L. H.
Tetrahedron 2001, 57, 1891-1896.
(13) Gunasekera, S. P.; McCarthy, P. J.; Kelly-Borges, M.; Lobkovsky, E.;
Clardy, J. J. Am. Chem. Soc. 1996, 118, 8759-8760.
(17) Samu, E.; Huszthy, P.; Somogyi, L.; Hollo´si, M. Tetrahedron: Asymmetry
1999, 10, 2775-2795.
9
13172 J. AM. CHEM. SOC. VOL. 124, NO. 44, 2002